stp707

STP707 is an investigational RNA interference (RNAi) therapeutic composed of two small interfering RNA (siRNA) oligonucleotides targeting transforming growth factor-beta 1 (TGF-β1) and cyclooxygenase-2 (COX-2) mRNAs. These siRNAs are formulated in nanoparticles using a Histidine-Lysine Co-polymer (HKP+H) peptide as the carrier. The dual inhibition of TGF-β1 and COX-2 is designed to produce synergistic immunomodulatory and antineoplastic effects by reducing pro-inflammatory factors implicated in tumorigenesis. Preclinical studies have shown that intravenous administration of STP707 results in knockdown of TGF-β1 and COX-2 gene expression across various organs, including liver, lung, and xenograft tumors. Clinically, it has demonstrated a strong safety profile with stable disease activity in heavily pre-treated patients with solid tumors such as pancreatic cancer. The drug is being developed primarily for the treatment of solid tumors—including liver cancer—and fibrotic diseases such as hepatic fibrosis and primary sclerosing cholangitis[1][2][5][6][7].